ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1793

Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus

Konstantinos Tselios1, Dafna Gladman2, Jiandong Su2 and Murray Urowitz2,3, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Antimalarial drugs and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Elevated muscle enzymes in the course of systemic lupus erythematosus (SLE) usually represent active myositis or drug-related toxicity. Lipid-lowering agents and, less frequently, antimalarials (chloroquine, CQ and hydroxychloroquine, HCQ) have been implicated. Aim of this observational cohort study was to delineate the possible role of antimalarials in inducing myotoxicity.

Methods: Patients with SLE have been followed prospectively s according to a standard protocol at 2-6 month interval. From this cohort we identified 325 patients who had elevated muscle enzymes, defined as abnormal creatine phosphokinase (CPK) measurements in at least two consecutive visits. Fifty-four patients on statins/fibrates and/or myositis were excluded. The final cohort of 271 patients (cases) were compared to 1453 patients who never had elevated CPK levels during their follow-up (controls) with regard to epidemiological variables and antimalarial treatment. Statistical software SAS (version 9.3) was used for analysis; p<0.05 was considered significant.

Results: Cases and controls did not differ with regard to gender, age at disease diagnosis and disease duration. Controls were characterised by higher disease activity and cumulative damage. Black patients were more commonly had elevated CPK levels (57/271, 21% vs. 143/1453, 9.8%, p<0.001). Antimalarial use was more frequent in cases (216/271, 79.7% vs 821/1453, 56.5%, p<0.001). Total frequency of elevated CPK in antimalarial users was 216/1322, 16.3%. Duration of antimalarial use was longer in patients with elevated CPK levels (4.33±4.96 years vs. 3.84±5.47 years, p<0.001). Cox multiple regression analysis showed antimalarials to be strong predictors for CPK elevation [HR=8.6 (CI=5.7-13) for CQ, p<0.001 and HR=7.4 (CI=5.2-10.4) for HCQ, p<0.001]. The cumulative CQ dose before the first abnormal CPK measurement was 148±324g in 2.0±4.4 years; for HCQ that was 307±426g in 2.6±3.6 years. In all patients CPK levels did not exceed 2-4x the upper limit of normal regardless of the duration of therapy. Over 7.3±5.6 years of follow-up, 18 patients (8.3%) developed clinical myopathy with proximal muscle weakness of the lower limbs. Of 203/216 patients who had more than 2 subsequent clinic visits after the second visit with elevated CPK and continued taking antimalarials, 101 (49.8%) patients had persistent enzyme elevation, 30 (14.8%) had intermittent elevation whereas in 72 (35.4%) CPK normalised immediately or shortly after that visit. Of note, one patient developed HCQ-induced cardiomyopathy after 13 years and a cumulative dose of 1623g.

Conclusion: Chronic antimalarial use is a risk factor for muscle enzyme elevation in SLE patients. In the vast majority of patients, CPK elevation remains a biochemical abnormality as it evolves to clinical myopathy in less than 10%; however, it persists in almost two thirds of the patients with continuous antimalarial treatment. Further studies are needed to assess abnormal CPK value in predicting serious outcomes, such as cardiomyopathy.      


Disclosure: K. Tselios, None; D. Gladman, None; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman D, Su J, Urowitz M. Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/is-there-a-relationship-between-antimalarial-treatment-and-elevated-muscle-enzymes-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-there-a-relationship-between-antimalarial-treatment-and-elevated-muscle-enzymes-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology